The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Lipid nanoparticle-mediated lymph node–targeting delivery of mRNA cancer vaccine elicits robust CD8 + T cell response
Open accessAbstract
The targeted delivery of messenger RNA (mRNA) to desired organs remains a great challenge for in vivo applications of mRNA technology. For mRNA vaccines, the targeted delivery to the lymph node (LN) is predicted to reduce side effects and increase the immune response. In this study, we explored an endogenously LN-targeting lipid nanoparticle (LNP) without the modification of any active targeting ligands for developing an mRNA cancer vaccine. The LNP named 113-O12B showed increased and specific expression in the LN compared with LNP formulated with ALC-0315, a synthetic lipid used in the COVID-19 vaccine Comirnaty. The targeted delivery of mRNA to the LN increased the CD8 + T cell response to the encoded full-length ovalbumin (OVA) model antigen. As a result, the protective and therapeutic effect of the OVA-encoding mRNA vaccine on the OVA-antigen–bearing B16F10 melanoma model was also improved. Moreover, 113-O12B encapsulated with TRP-2 peptide (TRP2 180–188 )–encoding mRNA also exhibited excellent tumor inhibition, with the complete response of 40% in the regular B16F10 tumor model when combined with anti–programmed death-1 (PD-1) therapy, revealing broad application of 113-O12B from protein to peptide antigens. All the treated mice showed long-term immune memory, hindering the occurrence of tumor metastatic nodules in the lung in the rechallenging experiments that followed. The enhanced antitumor efficacy of the LN-targeting LNP system shows great potential as a universal platform for the next generation of mRNA vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Yunna, C., Mengru, H., Lei, W., & Weidong, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173090 · Cited by 2,454
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 694
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
Self-citationFitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
The effects of IL-6 on CD4 T cell responses
Dienz, O., & Rincon, M. (2009) · Clinical Immunology · doi:10.1016/j.clim.2008.08.018 · Cited by 526
Recent advances in mRNA vaccine technology
Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512
Qiu, M., Tang, Y., Chen, J., Muriph, R., Ye, Z., Huang, C., Evans, J., Henske, E. P., & Xu, Q. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116271119 · Cited by 504
Self-citationCreech, C. B., Walker, S. C., & Samuels, R. J. (2021) · JAMA · doi:10.1001/jama.2021.3199 · Cited by 415
Qiu, M., Glass, Z., Chen, J., Haas, M., Jin, X., Zhao, X., Rui, X., Ye, Z., Li, Y., Zhang, F., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020401118 · Cited by 409
Self-citationTailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Lymph node targeting strategies to improve vaccination efficacy
Jiang, H., Wang, Q., & Sun, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.009 · Cited by 297
Transfection Efficiency of Cationic Lipids with Different Hydrophobic Domains in Gene Delivery
Zhi, D., Zhang, S., Wang, B., Zhao, Y., Yang, B., & Yu, S. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900393r · Cited by 244
Li, Y., Su, Z., Zhao, W., Zhang, X., Momin, N., Zhang, C., Wittrup, K. D., Dong, Y., Irvine, D. J., & Weiss, R. (2020) · Nature Cancer · doi:10.1038/s43018-020-0095-6 · Cited by 233
Self-citationComparison of DNA and mRNA vaccines against cancer
Jahanafrooz, Z., Baradaran, B., Mosafer, J., Hashemzaei, M., Rezaei, T., Mokhtarzadeh, A., & Hamblin, M. R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.003 · Cited by 202
Kauffman, K. J., Mir, F. F., Jhunjhunwala, S., Kaczmarek, J. C., Hurtado, J. E., Yang, J. H., Webber, M. J., Kowalski, P. S., Heartlein, M. W., DeRosa, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.006 · Cited by 190
Liposome-based delivery of biological drugs
Thapa Magar, K., Boafo, G. F., Li, X., Chen, Z., & He, W. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.08.020 · Cited by 179
Aldén, M., Olofsson Falla, F., Yang, D., Barghouth, M., Luan, C., Rasmussen, M., & De Marinis, Y. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44030073 · Cited by 179
Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
Boettler, T., Csernalabics, B., Salié, H., Luxenburger, H., Wischer, L., Alizei, E. S., Zoldan, K., Krimmel, L., Bronsert, P., Schwabenland, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.040 · Cited by 123
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 115
Self-citationAnti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Yoshida, K., Okamoto, M., Sasaki, J., Kuroda, C., Ishida, H., Ueda, K., Ideta, H., Kamanaka, T., Sobajima, A., Takizawa, T., et al. (2020) · BMC Cancer · doi:10.1186/s12885-019-6499-y · Cited by 108
Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides
Moss, K. H., Popova, P. G., Hadrup, S. R., Astakhova, K., & Taskova, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01290 · Cited by 104
Cancer/testis antigens: from serology to mRNA cancer vaccine
Fan, C., Qu, H., Wang, X., Sobhani, N., Wang, L., Liu, S., Xiong, W., Zeng, Z., & Li, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.016 · Cited by 79
Self-citationEnhancement of Immunity by a DNA Melanoma Vaccine against TRP2 with CCL21 as an Adjuvant
Yamano, T., Kaneda, Y., Huang, S., Hiramatsu, S. H., & Hoon, D. S. �. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.018 · Cited by 67
Shear-responsive peptide/siRNA complexes as lung-targeting gene vectors
Yin, D., Zhang, M., Chen, J., Huang, Y., & Liang, D. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.12.005 · Cited by 20
Self-citation
Cited by
mRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 371
Billingsley, M. M., Gong, N., Mukalel, A. J., Thatte, A. S., El‐Mayta, R., Patel, S. K., Metzloff, A. E., Swingle, K. L., Han, X., Xue, L., et al. (2024) · Small · doi:10.1002/smll.202304378 · Cited by 268
Circular RNA vaccine in disease prevention and treatment
Niu, D., Wu, Y., & Lian, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01561-x · Cited by 267
Metadata
- Authors
- Chen, J., Ye, Z., Huang, C., Qiu, M., Song, D., Li, Y., & Xu, Q.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2022-08-15
- Volume
- 119
- Issue
- 34
- Pages
- e2207841119-e2207841119
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W4291804571
- Cited by
- 422
- References
- 32
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.